Yesterday, Nano-X Imaging (Nasdaq: NNOX) reported Q3 2022 earnings and provided a business update. During the quarter, the Company leveraged the feedback it received from FDA regarding its Q submission as well as the learnings from its first regulatory submission, to file an updated 510(k) premarket noficaon for its mul-source 3D digital tomosynthesis system, the Nanox.ARC. As it is our understanding that the submission covered the commercial ready mul-source system, the Company can commence system deployments upon receiving the greenlight from the agency, which we esmate could occur in H1 2023. While it awaits FDA’s decision, NNOX has shied its focus to OUS geographies that do not view FDA clearance as a prerequisite for their own regulatory process, such as Nigeria.